跳至主要内容
临床试验/NL-OMON40925
NL-OMON40925已完成不适用

A study investigating the biological availability of ALX-0061, a new drug in the treatment of rheumatoid arthritis, after subcutaneous and intravenous administration in healthy volunteers. - ALX-0061 phase I bioavailability study in healthy volunteers.

Ablynx NV0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Ablynx NV
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Healthy male or female volunteers
  • Age between 18 and 55 years
  • BMI between 18.0 - 30.0 kg/m2

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

研究者

发起方
Ablynx NV

相似试验